31 jul: Vestas/CEO: Finansieringen er kun et midlertidigt problem
31 jul: Danske/Goldman: Løfter kursmål til 120 kr. fra 112 kr.
31-07-2012 15:43:00

Auxilium Swings to First Quarterly Profit as Revenue Grows

Relateret indhold

By Chelsea Stevenson

Auxilium Pharmaceuticals Inc. (AUXL) posted its first profitable period in the second quarter as the specialty biopharmaceutical company saw double-digit revenue growth.

The company raised its revenue estimate for the year to $310 million to $332 million, from $293 million to $315 million.

The company's two main drugs are Xiaflex, which is currently allowed in the U.S. and Europe to treat some adults suffering from Dupuytren's contracture in a person's fingers that aren't able to fully extend from the palm, and testosterone replacement therapy Testim.

Auxilium plans to file with the U.S. Food and Drug Administration seeking approval for the potential use of Xiaflex in the treatment of certain penile dysfunction by the end of 2012. Analysts at RBC Capital Markets estimate the potential U.S. market for Peyronie's disease stands at more than $100 million. Meanwhile, the company has a deal with GlaxoSmithKline PLC (GSK) to promote Testim.

"For the remainder of 2012 and beyond, we will continue to focus on delivering excellence in commercial execution and we anticipate a positive additional impact from GlaxoSmithKline's efforts on Testim's growth," Chief Executive Adrian Adams said. "We also look forward to filing the sBLA [supplemental biologics license application] for Xiaflex for the treatment of Peyronie's disease by the end of the year as we seek to obtain FDA approval for this indication."

For the period ended June 30, Auxilium posted a profit of $7.7 million, of 16 cents a share, compared with a loss of $5.1 million, of 11 cents a share, in the year-ago period. The latest quarter includes stock-based compensation expense of $3.9 million, compared with a $4 million expense last year.

Revenue rose 19% to $78.2 million, primarily due to increases in U.S. sales where Xiaflex revenue climbed 21% and Testim revenue rose 26%.

Gross margin narrowed to 77% from 78% due to the high margin catch-up amortization that was recognized last year from Xiaflex.

By drug, Auxilium is raising its full-year guidance for global Testim revenue to $245 million to $255 million from $225 million to $235 million but cut its outlook for global Xiaflex revenue to $65 million to $77 million from $68 million to $80 million.

Shares closed Monday at $25.77 and were inactive premarket. The stock is up 44% in the past three months.

Write to Chelsea Stevenson at chelsea.stevenson@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 31, 2012 09:43 ET (13:43 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/tendens: Dongs solgte olieforretning tager fokus - NY

24-05-2017 08:18:00
Dong stryger i fokus onsdag morgen med en aftale om salg af sin olie- og gasforretning inden den forlængede weekend. Forretningsdelen blev sat til salg i efteråret, og køberen er Ineos, der tidligere har været rygtet som mulig køber.Prisen kan løbe op i 8,7 mia. kr. og ændrer ikke ved 2017-forventningerne. Dong-aktien steg tirsdag 0,6 pct. til 281,80 kr.C20 Cap-indekset sluttede tirsdag med en sti..

KORR: Topdanmark Q1: Gode resultater giver plads til opjustering

23-05-2017 16:10:36
(Korr: Periodens resultat i Q1 17 er rettet i tabel)Forsikringskoncernen Topdanmark kom ud af det første kvartal i år med et nettooverskud på 415 mio. kr., hvilket var bedre end analytikernes forventninger, og selskabet opjusterer forventningerne til 2017.Ifølge et estimat, som Ritzau Estimates har indsamlet, havde analytikerne ventet et overskud på 318 mio. kr. i kvartalet.I samme periode af 2016..

Gigantisk vindprojekt går efter 100 pct. PTC trods 2021/23-afslutning

23-05-2017 14:04:08
Et selskab under Denver-baserede The Anschutz Corporation, som den amerikanske multimilliardær Philip Anschutz står bag, går efter at få tildelt PTC-støtte til den fulde sats, selv om halvdelen af det gigantiske vindprojekt på 3000 megawatt først planlægges opført i 2021-2023.Det bekræfter udviklingsselskabet bag projektet, Power Company of Wyoming (PCW), over for Ritzau Finans.Hos Sydbank betegne..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Gigantisk vindprojekt går efter 100 pct. PTC trods 2021/23-afslutning
2
Trump holder fingrene fra medicinpriserne i USA trods kritik - citat
3
Aktier/middag: Tunge spillere som Novo sender C20 sydover
4
Zealand: Partner ser mulighed for kunstig bugspytkirtel i 2020/21
5
Tirsdagens aktier: Topdanmark stjal scenen på stille dag for C20

Relaterede aktiekurser

Glaxosmithkline PLC ORD .. 1.636,50 0,4% Stigning i aktiekurs
GlaxoSmithKline PLC 42,96 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. maj 2017 10:03:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170517.1 - EUROWEB6 - 2017-05-24 10:03:59 - 2017-05-24 10:03:59 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x